1. Background
2. Methods
2.1. Study Population
2.2. Campaign Program
2.3. Instrument Validation
2.4. Survey
2.5. Ethical Considerations
2.6. Statistical Analysis
3. Results
| Questions | T1b | T2c | T3d | P1/P2/P3e |
|---|---|---|---|---|
| Q1. What is the most prevalent transmission route of HBV in Iran? | ||||
| (1: Unsafe injection / 2f: Mother to infant / 3: Unsafe Barbershops / 4: Unsafe cupping) | 21 (23.1) | 30 (33) | 71 (78) | 0.004/< 0.001 /< 0.001 |
| Q2. What is the most prevalent transmission route of HCV in Iran? | ||||
| (1f: Unsafe injection / 2: Mother to infant / 3: Unsafe Barbershops / 4: Unsafe cupping) | 54 (59.3) | 82 (90.1) | 89 (97.8) | < 0.001/0.016 /< 0.001 |
| Q3. Which one has an effective vaccine? | ||||
| (1f: HBV / 2: HCV / 3: Both / 4: None) | 79 (86.8) | 81 (89) | 91 (100) | 0.500/0.002/< 0.001 |
| Q4. Can a hepatitis B patient marry without transmitting it to his/her spouse? | ||||
| (1f: Yes / 2: No) | 55 (60.4) | 82 (90.1) | 91 (100) | < 0.001/ 0.004/< 0.001 |
| Q5. Can women with hepatitis B become pregnant and give birth to a healthy baby? | ||||
| (1f: Yes / 2: No) | 63 (69.2) | 84 (92.3) | 91 (100) | < 0.001/0.014/< 0.001 |
| Q6. Chronic HBV… | ||||
| (1: Can be cured / 2f: Can be controlled / 3: Both 1 and 2) | 52 (57.1) | 59 (64.8) | 89 (97.8) | 0.016/< 0.001/< 0.001 |
| Q7. Do inactive HBV carriers need treatment? | ||||
| (1: Yes / 2f: No) | 38 (41.8) | 54 (59.3) | 80 (87.9) | < 0.001/< 0.00/< 0.001 |
| Q8HBV and HCV infections can lead to | ||||
| (1: Cirrhosis / 2: Liver cancer / 3f: Both 1 and 2 / 4: None) | 60 (65.9) | 67 (73.6) | 90 (98.9) | 0.017/< 0.001/< 0.001 |
| Q9. Which one is the diagnostic test for HBV? | ||||
| (1: ALT / 2f: HBs-Ag / 3: HBs-Ab / 4: HBe-Ag) | 45 (49.45) | 65 (71.4) | 91 (100) | < 0.001/< 0.001/< 0.001 |
| Q10. Which one is the diagnostic test for HCV? | ||||
| (1: ALT / 2: HBc-Ab / 3f: HCV-Ab / 4: HCV-Ag) | 44 (48.35) | 76 (83.5) | 89 (97.8) | < 0.001/< 0.001/< 0.001 |
| Q11. Which one can transmit HBV and HCV? | ||||
| (1: Unsafe tattooing / 2: Unsafe cupping / 3: Unsafe injection / 4f: All) | 78 (85.7) | 80 (87.9) | 91 (100) | 0.250/0.002/< 0.001 |
| Q12. Which drug is used for the treatment of HBV? | ||||
| (1: PEG-interferon / 2: Tenofovir / 3: Adefovir / 4f: All) | 45 (49.45) | 75 (82.4) | 90 (98.9) | < 0.001/< 0.001/< 0.001 |
| Q13. Which drug is used for the treatment of HCV? | ||||
| (1: Tenofovir / 2: Lamivudine / 3f: Sofosbuvir / 4: All) | 27 (29.7) | 42 (46.15) | 85 (93.4) | < 0.001/< 0.001/< 0.001 |
| Q14. Can kissing and hugging transmit HBV and HCV? | ||||
| (1: Yes / 2f: No) | 64 (70.3) | 82 (90.1) | 91 (100) | < 0.001/0.004/< 0.001 |
| Q15. The minimum serum HBs-Ab titer for protection against HBV is… | ||||
| (1: 5 / 2f: 10 / 3: 100 / 4: 1000) | 42 (46.15) | 76 (83.5) | 90 (98.9) | < 0.001/< 0.001/< 0.001 |
| Total knowledge percentage (0 - 100) | 56.2 ± 18.0 | 75.8 ± 17.9 | 96.6 ± 6.1 | 0.001/0.003/< 0.001 |
aData are described as number (%) and mean ± standard deviation. HCV, hepatitis C virus; HBV, hepatitis B virus; ALT, alanine aminotransferase; HBs-Ag, hepatitis B surface antigen; HBc-Ab, hepatitis B core antibody; HBs-Ab, hepatitis B surface antibody; HCV-Ab, HCV antibody.
bBefore workshop (pretest, T1).
cAfter workshop (posttest, T2).
dAfter the campaign (final test, T3).
eP value for comparison between T1 and T2 (P1), P value for comparison between T1 and T3 (P2), and P value for comparison between T2 and T3 (P3).
fCorrect answer.
